

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract See the cover page and abstract (Pages 1 – 3) (b) Provide in the abstract an informative and balanced summary of what was done and what was found See the abstract (Pages 2 - 3)
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported See the introduction (Pages 4 – 5)
Objectives	3	State specific objectives, including any prespecified hypotheses See the introduction (Pages 4 – 5)
Methods		
Study design	4	Present key elements of study design early in the paper See the study setting, design and data source (Pages 5 - 6)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection See the study setting, design and data source and selection criteria in the methods (Pages 5 – 7)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants See the study setting, design and data source and selection criteria in the methods (Pages 5 – 7) (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable See the measures and statistical analyses in the methods (Pages 6 – 8)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group See the study setting, design and data source and measures in the methods (Pages 5 – 7)
Bias	9	Describe any efforts to address potential sources of bias See the classification details and methodology in the appendix (Page 24 - 25)
Study size	10	Explain how the study size was arrived at Not applicable

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why See the measures in the methods (Pages 6–7)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding See the statistical analyses in the methods (Pages 7–8) (b) Describe any methods used to examine subgroups and interactions Not applicable (c) Explain how missing data were addressed See the statistical analyses in the methods (Pages 7–8) (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy Not applicable (e) Describe any sensitivity analyses Not applicable

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed See the results (Page 8) and Figure S1 (b) Give reasons for non-participation at each stage See Figure S1 (c) Consider use of a flow diagram See Figure S1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders See the trends in sociodemographic characteristics in the results (Pages 9–10) and Table 1 (b) Indicate number of participants with missing data for each variable of interest See the statistical analyses in the methods (Pages 7–8) (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) Not applicable
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures See the trends in treatment utilization, trends in sociodemographic characteristics and trends in cannabis use frequency in the results (Pages 8–10), Figures 1–2, Tables 1–2 and Table S2
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included See the trends in treatment utilization, trends in sociodemographic characteristics and trends in cannabis use frequency in the results (Pages 8–10), Figures 1–2, Tables 1–2 and Table S2 (b) Report category boundaries when continuous variables were categorized Not applicable (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful

		time period Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Not applicable
Discussion		
Key results	18	Summarise key results with reference to study objectives See the main findings in the interpretation (Page 10)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias See the limitations in the interpretation (Pages 12 - 13)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence See the explanations and comparisons with other studies in the interpretation (Pages 11 – 12)
Generalisability	21	Discuss the generalisability (external validity) of the study results See the main findings in the interpretation (Page 10)
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based See the cover page (Page 1)

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.